Hopp til hovedinnhold

Anti-NMDA receptor encefalitt

Sist oppdatert: Sist revidert:
Sist revidert av:


  1. Dalmau J1, Armangué T2, Planagumà J3, Radosevic M3, Mannara F3, Leypoldt F4, Geis C5, Lancaster E6, Titulaer MJ7, Rosenfeld MR8, Graus F3. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019; Nov;18(11): 1045-1057. pmid:31326280 PubMed  
  2. Kalam S, Baheerathan A, McNamara C, Singh-Curry V. Anti-NMDAR encephalitis complicating pregnancy. Pract Neurol. 2018 Oct 10. pii: practneurol-2018-002042. PMID: 30305377 PubMed  
  3. Venkatesan A, Adatia K. Anti-NMDA-Receptor Encephalitis: From Bench to Clinic. ACS Chem Neurosci. 2017 Dec 20;8(12):2586-2595. PMID: 29077387 PubMed  
  4. Schein F1, Gagneux-Brunon A2, Antoine JC1, Lavernhe S1, Pillet S1, Paul S1, Frésard A1, Boutet C1, Grange R1, Cazorla C1, Lucht F1, Botelho-Nevers E1.. Anti-N-methyl-D-aspartate receptor encephalitis after Herpes simplex virus-associated encephalitis: an emerging disease with diagnosis and therapeutic challenges. Infection. 2017. pmid:27826871 PubMed  
  5. Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, Gleichman AJ, Balice-Gordon R, Rosenfeld MR, Lynch D, Graus F, Dalmau J. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13: 167-77. pmid:24360484 PubMed  
  6. Guasp M, Módena Y, Armangue T, Dalmau J, Graus F. Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm. 2020 Jan 3;7(2):e659. PMID: 31900318 PubMed  
  7. Chanson E, Bicilli É, Lauxerois M, Kauffmann S, Chabanne R, Ducray F, Honnorat J, Clavelou P, Rosenberg S. Anti-NMDA-R encephalitis: Should we consider extreme delta brush as electrical status epilepticus?. Neurophysiol Clin. 2016 Feb;46(1):17-25 . pmid:26922283 PubMed  
  8. Bost C, Chanson E, Picard G, Meyronet D, Mayeur ME, Ducray F, Rogemond V, Psimaras D, Antoine JC, Delattre JY, Desestret V, Honnorat J. Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. J Neurol. 2018 Jul 12. PMID: 30003358 PubMed  
  9. Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L, Torrents A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J. Late-onset anti-NMDA receptor encephalitis. Neurology. 2013 ; 81: 1058-63. pmid: 23946310 PubMed  
  10. Randall A, Huda S, Jacob A, Larner AJ. Autoimmune encephalitis (NMDAR antibody) in a patient receiving chronic post-transplant immunosuppression. Pract Neurol. 2018 Aug;18(4):320-322. PMID: 29588384 PubMed  
  11. Du L, Wang H, Zhou H, Chang H, Wei Y, Cong H, Xu W, Ma Y, Song T, Zhang X, Yin L. Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: A retrospective observational study. Medicine (Baltimore). 2020 Jul 31;99(31):e21238. PMID: 32756102 PubMed  
  12. Sonderen AV, Arends S, Tavy DLJ, Bastiaansen AEM, Bruijn MAAM, Schreurs MWJ, Sillevis Smitt PAE, Titulaer MJ.Predictive value of electroencephalography in anti-NMDA receptor encephalitis.J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1101-1106. PMID: 30135187 PubMed  
  13. Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernandez-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li Y, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer MJ; Autoimmune Encephalitis Alliance Clinicians Network. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):757-768. doi: 10.1136/jnnp-2020-325300. Epub 2021 Mar 1. PMID: 33649022; PMCID: PMC8223680.
  14. Abboud H, Probasco J, Irani SR, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernandez-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li Y, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer M; Autoimmune Encephalitis Alliance Clinicians Network. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021 Mar 1;92(8):897–907. doi: 10.1136/jnnp-2020-325302. Epub ahead of print. PMID: 33649021 PubMed  
  15. Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M; International NMDAR Antibody Encephalitis Consensus Group, Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021 Sep 20:e213188. doi: 10.1001/jamaneurol.2021.3188. Epub ahead of print. PMID: 34542573 PubMed  
  16. Gong X, Luo R, Liu J, Guo K, Li A, Liu X, Liu Y, Zhou D, Hong Z. Efficacy and tolerability of intravenous immunoglobulin versus intravenous methylprednisolone treatment in anti-N-methyl-d-aspartate receptor encephalitis. Eur J Neurol. 2022 Apr;29(4):1117-1127. doi: 10.1111/ene.15214. Epub 2022 Jan 9. PMID: 34918418. PubMed  
  17. Scheibe F, Prüss H, Mengel AM, Kohler S, Nümann A, Köhnlein M, Ruprecht K, Alexander T, Hiepe F, Meisel A. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology. 2017 Jan 24;88(4):366-370 . pmid:28003505 PubMed  
  18. Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, Psimaras D, Antoine JC, Delattre JY, Groc L, Leboyer M, Honnorat J. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm. 2016 Aug 29;3(5):e280 . pmid:27606355 PubMed  
  19. de Bruijn MAAM1, van Sonderen A1, van Coevorden-Hameete MH1, Bastiaansen AEM1, Schreurs MWJ1, Rouhl RPW1, van Donselaar CA1, Majoie MHJM1, Neuteboom RF1, Sillevis Smitt PAE1, Thijs RD1, Titulaer MJ2.. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology. 2019. pmid:30979857 PubMed  
  20. Gabilondo I, Saiz A, Galán L, González V, Jadraque R, Sabater L, Sans A, Sempere A, Vela A, Villalobos F, Viñals M, Villoslada P, Graus F. Analysis of relapses in anti-NMDAR encephalitis. Neurology 2011; 77: 996-9. pmid: 21865579 PubMed  
  21. Heine J, Kopp UA, Klag J, Ploner CJ, Prüss H, Finke C. Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Ann Neurol. 2021 Sep 30. doi: 10.1002/ana.26241. Epub ahead of print. PMID: 34595771. PubMed  
  22. Keddie S, Crisp SJ, Blackaby J, Cox A, Coles A, Hart M, Church AJ, Vincent A, Zandi M, Lunn MP. Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment.Eur J Neurol. 2018 Nov;25(11):1384-1388. PMID: 30035842 PubMed  
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med